Nevertheless, both the chemo > STING/α-PD-1 + α-CTLA-4 and the chemo > NLRP3/α-PD-1 + α-CTLA-4 groups showed slower tumor growth than the chemo > α-PD-1 + α-CTLA-4 group, respectively, especially the NLRP3 agonist-based combination therapy, which reached statistical significance (Fig. 1C). The gene discussed is NLRP3; the disease is neoplasm.